Thumbnail Image
Publication

Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)

Hernando, Cubero J
; 
Grande, E
; 
Gauna, DC
; 
Ibrahim, T
; 
Fazio, N
; 
Lopez, C
; 
Teule, A
; ; 
Alonso, V
; 
Molina-Cerrillo, J
... show 10 more
Citations
Altmetric:
Abstract
Authors
Hernando, Cubero J
Grande, E
Gauna, DC
Ibrahim, T
Fazio, N
Lopez, C
Teule, A
Valle, Juan W
Alonso, V
Molina-Cerrillo, J
Tafuto, S
Custodio, A
Trejo, L
Casteras, A
Kopp, RM
Miqueo, C
Herrera, MR
Garcia-Carbonero, R
Salazar, R
Capdevila, J
Affiliation
Medical Oncology, Vall d'Hebron University Hospital, Barcelona
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL. Conference abstract
Adobe PDF, 76.03 KB
Keywords
Type
Meetings and Proceedings
Citation
Hernando Cubero J, Grande E, Castellano Gauna D, Ibrahim T, Fazio N, Lopez C, et al. 1387P Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs). Annals of Oncology. 2019;30(Supplement_5):567.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622592
Embedded videos